Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer

被引:64
作者
Marom, EM [1 ]
Aloia, TA
Moore, MB
Hara, M
Herndon, JE
Harpole, DH
Goodman, PC
Patz, EF
机构
[1] Duke Univ, Med Ctr, Dept Radiol, Durham, NC 27710 USA
[2] Duke Univ, Med Ctr, Dept Thorac Surg, Durham, NC 27710 USA
[3] Nagoya City Univ, Sch Med, Dept Radiol, Nagoya, Aichi, Japan
[4] Duke Univ, Med Ctr, Div Biometry, Durham, NC 27710 USA
关键词
glucose transporter; lung cancer; PET;
D O I
10.1016/S0169-5002(00)00250-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To correlate FDG activity on PET with the expression of glucose transporter proteins Glut-1 and Glut-3 in patients with early stag non-small cell lung cancer (NSCLC). Methods: Over a 5 year period, all patients with a PET scan and clinical stage I NSCLC underwent an immunohistochemical analysis of their tumor for Glut-1 and Glut-3 expression. The amount of FDG uptake in the primary lesion was measured by a standardized uptake ratio (SUR) and correlated with immunohistochemical results. Results: Seventy-three patients with a mean age of 66 years had clinical stage I disease. The final pathologic stage showed 64 patients with stage IA/B disease, eight with stage IIA disease, and one patient with pathologic stage IIIA (T1N2) disease. Glut-1 transporter expression was significantly higher than Glut-3 (P < 0.0001), and although there was some association between the SUR and Glut-1 (P = 0.085) and SUR and Glut-3 (P = 0.074) expression, this did not reach statistical significance. Conclusions: Glut-1 and Glut-3 transporter expression did not demonstrate a statistically significant correlation with FDG uptake in potentially resectable lung cancer. It appears that these transporters alone do not affect the variation in FDG activity in early stage NSCLC. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:99 / 107
页数:9
相关论文
共 30 条
[1]  
Aloj L, 1999, CANCER RES, V59, P4709
[2]  
Brown RS, 1999, J NUCL MED, V40, P556
[3]  
BUSTAMANTE E, 1981, J BIOL CHEM, V256, P8699
[4]   PET and [F-18]-FDG in oncology: A clinical update [J].
Conti, PS ;
Lilien, DL ;
Hawley, K ;
Keppler, J ;
Grafton, ST ;
Bading, JR .
NUCLEAR MEDICINE AND BIOLOGY, 1996, 23 (06) :717-735
[5]   DECISION LOGIC FOR RETREATMENT OF ASYMPTOMATIC LUNG-CANCER RECURRENCE EASED ON POSITRON EMISSION TOMOGRAPHY FINDINGS [J].
FRANK, A ;
LEFKOWITZ, D ;
JAEGER, S ;
GOBAR, L ;
SUNDERLAND, J ;
GUPTA, N ;
SCOTT, W ;
MAILLIARD, J ;
LYNCH, H ;
BISHOP, J ;
THORPE, P ;
DEWAN, N .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 32 (05) :1495-1512
[6]   ATYPICAL MANIFESTATIONS OF PULMONARY ADENOID CYSTIC CARCINOMA [J].
GALLAGHER, CG ;
STARK, R ;
TESKEY, J ;
KRYGER, M .
BRITISH JOURNAL OF DISEASES OF THE CHEST, 1986, 80 (04) :396-399
[7]   Dynamic positron emission tomography with F-18 fluorodeoxyglucose imaging in differentiation of benign from malignant lung/mediastinal lesions [J].
Gupta, N ;
Gill, H ;
Graeber, G ;
Bishop, H ;
Hurst, J ;
Stephens, T .
CHEST, 1998, 114 (04) :1105-1111
[8]   AUTOLOGOUS MIXED LYMPHOCYTE-REACTION (AMLR) IN MAN .16. THE AMLR AND MONOCLONAL ANTIBODY-DEFINED T-CELL SUBSETS AND HNK 1+ NATURAL-KILLER-CELLS IN NORMAL HUMAN-PREGNANCY [J].
GUPTA, S ;
FANOUS, E .
JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 1986, 9 (01) :1-9
[9]   FDG UPTAKE, TUMOR PROLIFERATION AND EXPRESSION OF GLYCOLYSIS ASSOCIATED GENES IN ANIMAL TUMOR-MODELS [J].
HABERKORN, U ;
ZIEGLER, SI ;
OBERDORFER, F ;
TROJAN, H ;
HAAG, D ;
PESCHKE, P ;
BERGER, MR ;
ALTMANN, A ;
VANKAICK, G .
NUCLEAR MEDICINE AND BIOLOGY, 1994, 21 (06) :827-834
[10]  
HAMACHER K, 1986, J NUCL MED, V27, P235